Imagine your brain has tiny proteins that misfold and clump together like sticky glue, blocking signals and killing cells. This project created a pill that stops these clumps from forming in the first place. It uses a smart AI system to find the exact patients who will benefit most from the treatment based on their genetic makeup.
Current dementia treatments only slow progression and often have fatal side effects. There is a massive unmet need for disease-modifying therapies that can prevent the onset of the disease.
An oral drug (AT-001) and a precision-medicine platform using AI and big data to identify patients via biomarkers.
If you are a drug developer dealing with high failure rates in amyloid therapies — this project developed AT-001, an oral treatment that prevents toxic protein aggregation. It targets both amyloid and tau proteins to potentially prevent dementia onset rather than just slowing it.
If you are a clinic dealing with the lack of disease-modifying treatments for dementia — this project developed a precision-medicine platform using big data and AI. This allows for the identification of patients with validated biomarkers for targeted therapy.
If you are a biotech firm dealing with the difficulty of patient stratification in clinical trials — this project developed the DNACA platform. It uses deep learning algorithms to match specific genetic mutations, like Cystatin-C, to effective therapies.
Based on available project data, the specific price per dose or treatment cost is not disclosed; however, the project aims to reduce the global socio-economic costs of dementia estimated at €2.8 trillion by 2030.
The project has developed AT-001 as an oral treatment (NCE), which typically allows for easier industrial scaling and administration compared to injectable amyloid therapies.
Based on available project data, AT-001 is a new-chemical entity (NCE) developed by Arctic Therapeutics, though specific licensing terms are not provided.
The company has received EMA approval for a registration study and aims to bring the compound to market in early 2026.
It integrates via a precision-medicine platform that uses big data mining and AI to identify patients with validated biomarkers before administering the oral drug.
The project is led by a single SME, Arctic Therapeutics (Iceland), representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, moving rapidly from AI-driven discovery to clinical registration without the typical delays of academic-heavy consortia.
Contact Arctic Therapeutics EHF in Iceland regarding AT-001 licensing
Contact us to explore partnership opportunities with AI-driven precision medicine platforms.
